theophylline has been researched along with Basal Ganglia Diseases in 1 studies
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Further, neither catalepsy intensity nor its latency was affected by a combination of the selective A(1)R antagonist DPCPX (1 mg/kg), with the larger doses of both anticholinergics." | 5.36 | Synergism of theophylline and anticholinergics to inhibit haloperidol-induced catalepsy: a potential treatment for extrapyramidal syndromes. ( Arankowsky-Sandoval, G; Ceballos-Huerta, F; Góngora-Alfaro, JL; González-Lugo, OE; Jiménez-Capdeville, ME, 2010) |
| "Further, neither catalepsy intensity nor its latency was affected by a combination of the selective A(1)R antagonist DPCPX (1 mg/kg), with the larger doses of both anticholinergics." | 1.36 | Synergism of theophylline and anticholinergics to inhibit haloperidol-induced catalepsy: a potential treatment for extrapyramidal syndromes. ( Arankowsky-Sandoval, G; Ceballos-Huerta, F; Góngora-Alfaro, JL; González-Lugo, OE; Jiménez-Capdeville, ME, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Lugo, OE | 1 |
| Ceballos-Huerta, F | 1 |
| Jiménez-Capdeville, ME | 1 |
| Arankowsky-Sandoval, G | 1 |
| Góngora-Alfaro, JL | 1 |
1 other study available for theophylline and Basal Ganglia Diseases
| Article | Year |
|---|---|
Synergism of theophylline and anticholinergics to inhibit haloperidol-induced catalepsy: a potential treatment for extrapyramidal syndromes.
Topics: Animals; Basal Ganglia Diseases; Catalepsy; Cholinergic Antagonists; Drug Synergism; Drug Therapy, C | 2010 |